Athauda Arachchi Pandula, De Silva Sulakkana
General Sir John Kotelawala Defence University, Ratmalana, Sri Lanka.
Durdans Heart Centre, Colombo, Sri Lanka.
Int J Cardiol Congenit Heart Dis. 2025 Apr 8;20:100583. doi: 10.1016/j.ijcchd.2025.100583. eCollection 2025 Jun.
This reflective article explores the first reported case in literature of a transfemoral transcatheter aortic valve implantation (TAVI) in a dextrocardiac patient with severe aortic regurgitation (AR), left-sided superior vena cava (LSVC), and prohibitive surgical risk. It provides an overview of off-label TAVI for pure AR, aortic regurgitation without annular calcification, and in patients with rare congenital anomalies such as dextrocardia. The article discusses the technical, ethical, and procedural challenges, including device oversizing, the use of new-generation valves, and the risk of paravalvular leaks. The review also highlights recent advances in TAVI devices, procedural planning, and outcomes from multicenter studies and registries. The case underscores the importance of innovation, multidisciplinary collaboration, and the evolution of ethical frameworks to guide the safe expansion of TAVI into complex scenarios.
这篇反思性文章探讨了文献中首次报道的经股动脉经导管主动脉瓣植入术(TAVI)治疗一名患有严重主动脉瓣反流(AR)、左侧上腔静脉(LSVC)且手术风险极高的右位心患者的病例。它概述了用于单纯AR、无瓣环钙化的主动脉瓣反流以及患有右位心等罕见先天性异常患者的非标签TAVI。文章讨论了技术、伦理和程序方面的挑战,包括器械尺寸过大、新一代瓣膜的使用以及瓣周漏的风险。该综述还强调了TAVI器械、程序规划的最新进展以及多中心研究和注册登记的结果。该病例强调了创新、多学科合作以及伦理框架演变对于指导TAVI安全扩展至复杂情况的重要性。